Neurodegenerative Mapping and Phenotyping (NeuroMAP) at The Ohio State University Wexner Medical Center is an innovative research initiative dedicated to advancing our understanding of Alzheimer’s disease and related dementias.
By combining expertise in neuropathology, advanced imaging, molecular analysis and data science, NeuroMAP is redefining how researchers study the human brain. The center transforms postmortem human tissues into high-resolution molecular maps and living biological models—unlocking new insights into how neurodegenerative diseases develop, progress and respond to intervention.
At its core, NeuroMAP is designed to connect discoveries across systems. By studying both the brain and peripheral organs, researchers can better understand how disease manifests throughout the body, identify new biomarkers and uncover opportunities for earlier diagnosis and more personalized treatment approaches.
Why NeuroMAP Matters
NeuroMAP represents a bold step forward in neuroscience—bringing together clinical data, advanced technologies and human tissue research into a single, integrated platform.
This comprehensive approach allows investigators to move beyond traditional research models and generate deeper, more actionable insights into neurodegenerative disease. The center supports:
- Breakthrough discovery in Alzheimer’s disease and related dementias
- Biomarker identification for early detection and monitoring
- Development of new therapeutic strategies
- Integration of biological, clinical and environmental data for whole-person insights
An Integrated Research Ecosystem
NeuroMAP functions as a centralized hub that connects researchers, clinicians and departments across the university. By integrating imaging, molecular profiling, clinical outcomes and demographic data, the center creates a powerful, shared resource for interdisciplinary collaboration.